Increasing evidence indicates that IL3RA is highly expressed in leukemic stem cells but not in normal hematopoietic stem cells, and it associates in AML with treatment response, minimal residual disease detection, and prognosis [3,15,17]. Here, IL3RA is linked to acute myeloid leukemia.